share_log

Avalo Therapeutics | DEFA14A: Others

Avalo Therapeutics | DEFA14A: Others

Avalo Therapeutics | DEFA14A:其他
美股sec公告 ·  06/27 07:07
Moomoo AI 已提取核心訊息
Avalo Therapeutics, Inc., a biotechnology company listed in the United States, has filed definitive additional materials with the Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, is a standard procedure for companies preparing for upcoming shareholder meetings where proxy materials are provided to shareholders. Avalo Therapeutics confirmed that no filing fee was required for this submission. The materials filed are intended to provide shareholders with additional information ahead of the company's decision-making process.
Avalo Therapeutics, Inc., a biotechnology company listed in the United States, has filed definitive additional materials with the Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, is a standard procedure for companies preparing for upcoming shareholder meetings where proxy materials are provided to shareholders. Avalo Therapeutics confirmed that no filing fee was required for this submission. The materials filed are intended to provide shareholders with additional information ahead of the company's decision-making process.
生物技術公司Avalo Therapeutics, Inc.在美國上市,已經向美國證券交易委員會(SEC)提交了明確的額外材料,作爲其代理聲明的一部分。根據1934年證券交易法第14(a)條規定,此申報是爲參與即將舉行的股東會議做準備的公司進行的標準程序,屆時會向股東提供代理材料。Avalo Therapeutics證實此次提交不需要提交任何文件費用。提交的材料旨在在公司決策過程前爲股東提供更多信息。
生物技術公司Avalo Therapeutics, Inc.在美國上市,已經向美國證券交易委員會(SEC)提交了明確的額外材料,作爲其代理聲明的一部分。根據1934年證券交易法第14(a)條規定,此申報是爲參與即將舉行的股東會議做準備的公司進行的標準程序,屆時會向股東提供代理材料。Avalo Therapeutics證實此次提交不需要提交任何文件費用。提交的材料旨在在公司決策過程前爲股東提供更多信息。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息